Evidence map›Paper›PMID 37563650›Full record

ArticleStem cell research & therapy2023

Renal cancer secretome induces migration of mesenchymal stromal cells.

Piotr Popławski, Weronika Zarychta-Wiśniewska, Anna Burdzińska, Joanna Bogusławska, Anna Adamiok-Ostrowska, Karolina Hanusek, Beata Rybicka, Alex Białas, Helena Kossowska, Roksana Iwanicka-Nowicka and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Piotr PopławskiDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Weronika Zarychta-WiśniewskaDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Anna BurdzińskaDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Joanna BogusławskaDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Anna Adamiok-OstrowskaDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Karolina HanusekDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Beata RybickaDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Alex BiałasDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Helena KossowskaLaboratory of Systems Biology, Faculty of Biology, University of Warsaw, 02-106, Warsaw, Poland.
Roksana Iwanicka-NowickaLaboratory of Systems Biology, Faculty of Biology, University of Warsaw, 02-106, Warsaw, Poland.
Marta KoblowskaLaboratory of Systems Biology, Faculty of Biology, University of Warsaw, 02-106, Warsaw, Poland.
Leszek PączekDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Agnieszka Piekiełko-WitkowskaDepartment of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland. apiekielko@cmkp.edu.pl.ORCID http://orcid.org/0000-0002-5348-0760
Postgraduate School of Molecular Medicine · PLInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLMedical University of Warsaw · PLUniversity of Warsaw · PLWarsaw University of Life Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced renal cell carcinoma (RCC) is therapeutically challenging. RCC progression is facilitated by mesenchymal stem/stromal cells (MSCs) that exert remarkable tumor tropism. The specific mechanisms mediating MSCs' migration to RCC remain unknown. Here, we aimed to comprehensively analyze RCC secretome to identify MSCs attractants.

methodsConditioned media (CM) were collected from five RCC-derived cell lines (Caki-1, 786-O, A498, KIJ265T and KIJ308T) and non-tumorous control cell line (RPTEC/TERT1) and analyzed using cytokine arrays targeting 274 cytokines in addition to global CM proteomics. MSCs were isolated from bone marrow of patients undergoing standard orthopedic surgeries. RCC CM and the selected recombinant cytokines were used to analyze their influence on MSCs migration and microarray-targeted gene expression. The expression of genes encoding cytokines was evaluated in 100 matched-paired control-RCC tumor samples.

resultsWhen compared with normal cells, CM from advanced RCC cell lines (Caki-1 and KIJ265T) were the strongest stimulators of MSCs migration. Targeted analysis of 274 cytokines and global proteomics of RCC CM revealed decreased DPP4 and EGF, as well as increased AREG, FN1 and MMP1, with consistently altered gene expression in RCC cell lines and tumors. AREG and FN1 stimulated, while DPP4 attenuated MSCs migration. RCC CM induced MSCs' transcriptional reprogramming, stimulating the expression of CD44, PTX3 and RAB27B. RCC cells secreted hyaluronic acid (HA), a CD44 ligand mediating MSCs' homing to the kidney. AREG emerged as an upregulator of MSCs' transcription.

conclusionsAdvanced RCC cells secrete AREG, FN1 and HA to induce MSCs migration, while DPP4 loss prevents its inhibitory effect on MSCs homing. RCC secretome induces MSCs' transcriptional reprograming to facilitate their migration. The identified components of RCC secretome represent potential therapeutic targets.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMesenchymal Stem CellsCulture Media, ConditionedCytokinesDipeptidyl Peptidase 4HumansSecretomeCulture Media, ConditionedCytokinesDipeptidyl Peptidase 4AREGDPP4FN1Mesenchymal stromal cellsRenal cell cancer

Identifiers

PMID37563650
PMCPMC10413545
OpenAlexW4385724794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.